Toxicities of the platinum antineoplastic agents

Bibliography

• LASZLO J, LUCAS VS Jr: Emesis as a critical problem in chemotherapy. N Engl. J. Med. (1981) 306:948–949.
   Google Scholar
• VERWEIJ J, DE WIT R, DE MULDER PH: Optimal control of acute cisplatin-induced emesis. Onco/ogy (1996) 53\(Suppl. 1):56–64.
   Google Scholar
• VON HOFF DD, SCHILSKY R, REICHERT CM et al.: Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat. Rep. (1979) 63:1527–1531.
   PubMedGoogle Scholar
• HESKETH P: Management of cisplatin-induced delayed emesis. Oncology (1996) 53\(Suppl. 1):73–77.
   Google Scholar
• KRIS MG, GRALLA RJ, CLARK RA et al.: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. Clin. Oncol (1985) 3:1379–1384.
   Web of Science ®Google Scholar
• GRALLA RJ, ITRI LM, PISKO SE et al.: Antiemetic efficacy of high-dose metocloprarnide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl. J. Med. (1981) 305:905–909.
   PubMed Web of Science ®Google Scholar
• OSSI M, ANDERSON E, FREEMAN A: 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. Onco/ogy (1996) 53\(Suppl. 1):78–85.
   Google Scholar
• ROILA F, TONATO M, COGNETTI F et al.: Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J. Clin. Oncol (1991) 9:675–678.
   PubMed Web of Science ®Google Scholar
• GOODIN S, CUNNINGHAM R: 5-HT3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist (2002) 7:424–436.
   PubMed Web of Science ®Google Scholar
• KRIS MG, GRALLA RJ, TYSON LB, CLARK RA, CIRRINCIONE C, GROSHEN S: Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metocloprarnide plus dexamethasone in patients receiving cisplatin. j Clin. Oncol. (1989) 7:108–114.
   PubMed Web of Science ®Google Scholar
• HICKOK JT, ROSCOE JA, MORROW GR, KING DK, ATKINS JN, FITCH TR: Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptarnine-3 antiemetics: a University of Rochester James P Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer (2003) 97:2880–2886.
   PubMed Web of Science ®Google Scholar
• NAVARI RM, REINHARDT RR, GRALLA RJ et al.: Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N EngL J. Med. (1999) 340:190–195.
   PubMed Web of Science ®Google Scholar
• •Demonstration of the clinical utility of neurokinin-1 receptor antagonism to reduce the severity of platinum-associated delayed emesis.
   Google Scholar
• CAMPOS D, RODRIGUES PEREIRA J, REINHARDT RR et al.: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin. Oncol. (2001) 19:1759–1767.
   PubMed Web of Science ®Google Scholar
• VAN BELLE S, LICHINITSER MR, NAVARI RM et al.: Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer (2002) 94:3032–3041.
   PubMed Web of Science ®Google Scholar
• POLI-BIGELLI S, RODRIGUES-PEREIRA J, CARIDES AD et al.: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer (2003) 97:3090–3098.
   Google Scholar
• CHAWLA SP, GRUNBERG SM, GRALLA RJ et al.: Establishing the dose of the oral NKI antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer (2003) 97:2290–2300.
   PubMed Web of Science ®Google Scholar
• MARTIN M, DIAZ-RUBIO E, SANCHEZ A, ALMENAREZ J, LOPEZ-VEGA JM: The natural course of emesis after carboplatin treatment. Acta Oncol. (1990) 29:593–595.
   PubMed Web of Science ®Google Scholar
• DU BOIS A, VACH W, KIECHLE M, CRAMER-GIRAUD U, MEERPOHL HG: Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Onco/ogy (1996) 53\(Suppl. 0:46–50.
   Google Scholar
• MARKMAN M, KENNEDY A, WEBSTER K, KULP B, PETERSON G, BELINSON J: Control of carboplatin-induced emesis with a fixed low-dose of granisetron (0.5 mg) plus dexamethasone. Gynecol. Oncol. (1996) 60:435–437.
   PubMed Web of Science ®Google Scholar
• MARKMAN M, KENNEDY A, WEBSTER K, PETERSON G, KULP B, BELINSON J: The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy. Gynecol. Oncol. (2000) 78:43–46.
   PubMed Web of Science ®Google Scholar
• CULY CR, CLEMETT D, WISEMAN LR: Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs (2000) 60:895–924.
   Google Scholar
• CASSIDY J, MISSET JL: Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. (2002) 29:11–20.
   PubMed Web of Science ®Google Scholar
• MARKMAN M, KULP B, PETERSON G, KENNEDY A: Weekly carboplatin as a strategy to prevent severe treatment-related emesis. Gynecol. Oncol. (2000) 78:265.
   PubMed Web of Science ®Google Scholar
• OMURA G, BLESSING JA, EHRLICH CE et al.: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer (1986) 57:1725–1730.
   Google Scholar
• SWENERTON K, JEFFREY J, STUART Get al.: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized Phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin. Oncol. (1992) 10:718–726.
   Google Scholar
• ALBERTS DS, GREEN S, HANNIGAN EV et al.: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a Phase III randomized trial in Stages III and IV ovarian cancer./ Clin. Oncol. (1992) 10:706–717.
   PubMed Web of Science ®Google Scholar
• CASCINU S, FEDELI A, DEL FERRO E,LUZI FEDELI S, CATALANO G: Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. Clin. Owed. (1994) 12:1058–1062.
   PubMed Web of Science ®Google Scholar
• SEIDENFELD J, PIPER M, FLAMM C et al.: Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Nail. Cancer Inst. (2001) 93:1204–1214.
   PubMed Web of Science ®Google Scholar
• ••An excellent summary of the clinical utilityof erythropoietin in preventing and treating chemotherapy (including platinum)-associated anaemia.
   Google Scholar
• QUIRT I, ROBESON C, LAU CY et al.: Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. Clin. Oncol. (2001) 19:4126–4134.
   Web of Science ®Google Scholar
• HEDDENS D, ALBERTS DS, HANNIGAN EV et al.: Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol. Oncol. (2002) 86:239–243.
   PubMed Web of Science ®Google Scholar
• CELLA D, ZAGARI MJ, VANDOROS C, GAGNON DD, HURTZ HJ, NORTIER JW: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J. Clin. Oncol. (2003) 21:366–373.
   PubMed Web of Science ®Google Scholar
• ALBERTS DS, DORR RT: New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. Oncologist (1998) 3:15–34.
   PubMedGoogle Scholar
• CALVERT AH, NEWELL DR, GUMBRELL LA et al.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin. Oncol. (1989) 7:1748–1756.
   PubMed Web of Science ®Google Scholar
• •Demonstration of the importance of dosing carboplatin based on a calculated AUG (including renal function), rather than body surface area.
   Google Scholar
• VAN WARMERDAM LJ, RODENHUIS S, TEN BOKKEL HUININK WW, MAES RA, BEIJNEN JH: The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res. Clin. Oncol. (1995) 121:478–486.
   PubMed Web of Science ®Google Scholar
• TEN BOKKEL HUININK WW, VAN WARMERDAM LJ, HELMERHORST TJ, SCHAEFERS MC, BEIJNEN JH, RODENHUIS S: Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. Ann. Oncol. (1997) 8:351–354.
   PubMed Web of Science ®Google Scholar
• PERTUSSINI E, RATAJCZAK J, MAJKA M, VAUGHN D, RATAJCZAK MZ, GEWIRTZ AM: Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood (2001) 97:638–644.
   PubMed Web of Science ®Google Scholar
• STEWART DJ, DULBERG CS, MIKHAEL NZ, REDMOND MD, MONTPETIT VA, GOEL R: Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother. Pharmacol. (1997) 40:293–308.
   PubMed Web of Science ®Google Scholar
• PINZANI V, BRESSOLLE F, HAUG IJ, GALTIER M, BLAYAC JP, BALMES P: Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother. Pharmacol. (1994) 35:1–9.
   PubMed Web of Science ®Google Scholar
• KEMP G, ROSE P, LURAIN J et cll.: Amifostine pretreatment for protection against cyclophospharnide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. (1996) 14:2101–2112.
   Google Scholar
• ROSE PG, BUNDY BN, WATKINS EB et al.: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl. J. Med. (1999) 340:1144–1153.
   PubMed Web of Science ®Google Scholar
• KEYS HM, BUNDY BN, STEHMAN FB et al.: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage IB cervical carcinoma. N. Engl. J. Med. (1999) 340:1154–1161.
   PubMed Web of Science ®Google Scholar
• •Demonstration of the safety and efficacy of concurrent cisplatin and radiation in locally-advanced cervical cancer.
   Google Scholar
• HAUSHEER FH, KANTER P, GAO S et al.: Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin. Oncol. (1998) 25:584–599.
   PubMed Web of Science ®Google Scholar
• BLACHLEY JD, HILL JB: Renal and electrolyte disturbances associated with cisplatin. Ann. Intern. Med. (1981) 95:628–632.
   PubMed Web of Science ®Google Scholar
• BUCKLEY JE, CLARK VL, MEYER TJ, PEARLMAN NW: Hypomagnesemia after cisplatin combination chemotherapy. Arch. Intern. Med. (1984) 144:2347–2348.
   PubMed Web of Science ®Google Scholar
• SCHILSKY RI,, ANDERSON T: Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann. Intern. Med. (1979) 90:929–931.
   PubMed Web of Science ®Google Scholar
• GONZALEZ C, VILLASANTA U: Life-threatening hypocalcemia and hypomagnesemia associated with cisplatin chemotherapy. Obstet. Gynecol. (1982) 59:732–734.
   PubMed Web of Science ®Google Scholar
• HAYES FA, GREEN AA, SENZER N, PRATT CB: Tetany: a complication of cis-dichlorodiammineplatinum(II) therapy. Cancer Treat. Rep. (1979) 63:547–548.
   PubMedGoogle Scholar
• SCHILSKY RL, BARLOCK A, OZOLS RF: Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat. Rep. (1982) 66:1767–1769.
   PubMedGoogle Scholar
• HARTMANN JT, FELS LM, FRANZKE A et al.: Comparative study of the acute nephrotoxicity from standard dose cisplatin ± ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Anticancer Res. (2000) 20:3767–3774.
   PubMed Web of Science ®Google Scholar
• PINOTTI G, MARTINELLI B: A case of acute tubular necrosis due to oxaliplatin. Ann. Oncol. (2002) 12:1951–1955.
   Google Scholar
• PICCART MJ, BERTELSEN K, JAMES K et al.: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophospharnide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. (2000) 92:699–708.
   PubMed Web of Science ®Google Scholar
• DREICER R, MANOLA J, ROTH BJ, COHEN MB, HATFIELD AK, WILDING G: Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. (2000) 18:1058–1061.
   PubMed Web of Science ®Google Scholar
• CONNELLY E, MARKMAN M, KENNEDY A et al.: Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol. Oncol. (1996) 62:166–168.
   PubMed Web of Science ®Google Scholar
• WARNER E: Neurotoxicity of cisplatin andtaxol. Int. J. Gynecol. Cancer (1995) 5:161–169.
   PubMed Web of Science ®Google Scholar
• CERSOSIMO RJ: Cisplatin neurotoxicity. Cancer Treat. Rev. (1989) 16:195–211.
   PubMed Web of Science ®Google Scholar
• THOMPSON SW DAVIS LE, KORNFELD M, HILGERS RD, STANDEFER JC: Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer (1984) 54:1269–1275.
   Google Scholar
• GILL JS, WINDEBANK AJ: Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. Clin. Invest. (1998) 101:2842–2850.
   Google Scholar
• TUXEN MK, HANSEN SW: Neurotoxicity secondary to antineoplastic drugs. Cancer Treat. Rev. (1994) 20:191–214.
   PubMed Web of Science ®Google Scholar
• VON SCHLIPPE M, FOWLER CJ, HARLAND SJ: Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br. J. Cancer (2001) 85:823–826.
   PubMed Web of Science ®Google Scholar
• GREGG RW, MOLEPO JM, MONPETIT VJ et al.: Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. Clin. Oncol. (1992) 10:795–803.
   Web of Science ®Google Scholar
• NEIJT JP, ENGELHOLM SA, TUXEN MKet al.: Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. (2000) 18:3084–3092.
   Google Scholar
• PARMAR MK, LEDERMANN JA, COLOMBO N et al.; ICON4/AGO-OVAR-2.2 trial: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 361:2099–2106.
   Google Scholar
• GAMELIN E, GAMELIN L, BOSSI L, QUASTHOFF S: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin. Oncol. (2002) 29\(Suppl. 15):21–33.
   Google Scholar
• WILSON RH, LEHKY T, THOMAS RR, QUINN MG, FLOETER MK, GREM JL: Acute oxaliplatin-induced peripheral nerve hyperexcitability. j Clin. Oncol. (2002) 20:1767–1774.
   PubMed Web of Science ®Google Scholar
• TAIEB S, TRILLET-LENOIR V, RAMBAUD L, DESCOS L, FREYER G: Lhermitte sign and urinary retention. Atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer (2002) 94:2434–2440.
   Google Scholar
• PACE A, SAVARESE A, PICARDO M et al.: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J. Clin. Oncol. (2003) 21:927–931.
   PubMed Web of Science ®Google Scholar
• ALBERTS DS, NOEL JK: Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs (1995) 6:369–383.
   PubMed Web of Science ®Google Scholar
• CASCINU S, CORDELLA L, DEL FERRO E, FRONZONI M, CATALANO G: Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J. Clin. Oncol. (1995) 13:26–32.
   PubMed Web of Science ®Google Scholar
• ROBERTS JA, JENISON EL, KIM KM, CLARKE-PEARSON D, LANGLEBEN A: A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol. Oncol. (1997) 67:172–177.
   PubMed Web of Science ®Google Scholar
• COLOMBO N, BINI S, MICELI D et al.: Weekly cisplatin ± glutathione in relapsed ovarian carcinoma. Int. J Gynecol. Cancer (1995) 5:81–86.
   PubMed Web of Science ®Google Scholar
• BERG AL, SPITZER JB, GARVIN JH Jr: Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope (1999) 109:1806–1814.
   PubMed Web of Science ®Google Scholar
• AGUILAR-MARKULIS NV, BECKLEY S, PRIORE R, METTLIN C: Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol. (1981) 16:111–123.
   PubMed Web of Science ®Google Scholar
• NAGY JL, ADELSTEIN DJ, NEWMAN CW, RYBICKI LA, RICE TW LAVERTU P: Cisplatin ototoxicity. The importance of baseline audiometry. Am. J Clin. Oncol. (1999) 22:305–308.
   PubMed Web of Science ®Google Scholar
• POLLERA CF, MAROLLA P, NARDI M, AMEGLIO F, COZZO L, BEVERE F: Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer Chemother. Pharmacol. (1988) 21:61–64.
   PubMed Web of Science ®Google Scholar
• BLAKLEY BW, GUPTA AK, MYERS SF, SCH WAN S: Risk factors for ototoxicity due to cisplatin. Arch. Otalaryngol. Head Neck Surg. (1994) 120:541–546.
   PubMed Web of Science ®Google Scholar
• LAURELL G, BESKOW C, FRANKENDAL B, BORG E: Cisplatin administration to gynecologic cancer patients. Long term effects on hearing. Cancer (1996) 78:1798–1804.
   Google Scholar
• STIFF PJ, MCKENZIE RS, ALBERTS DS et al.: Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. J. Clin. Oncol. (1994) 12:176–183.
   PubMed Web of Science ®Google Scholar
• OSTROW S, HAHN D, WIERNIK PH, RICHARDS RD: Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy. Cancer Treat. Rep. (1978) 62:1591–1594.
   PubMedGoogle Scholar
• WALSH TJ, CLARK AW, PARHAD IM, GREEN WR: Neurotoxic effects of cisplatin therapy. Arch. Neural. (1982) 39:719–720.
   PubMed Web of Science ®Google Scholar
• DIAMOND SB, RUDOLPH SH, LUBICZ SS, DEPPE G, COHEN CJ: Cerebral blindness in association with cis-platinum chemotherapy for advanced carcinoma of the fallopian tube. Obstet. Gynecol. (1982) 59:S84–S86.
   Web of Science ®Google Scholar
• BERMAN IJ, MANN MP: Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer (1980) 45:764–766.
   PubMed Web of Science ®Google Scholar
• MEAD GM, ARNOLD AM, GREEN JA, MACBETH FR, WILLIAMS CJ, WHITEHOUSE JM: Epileptic seizures associated with cisplatin administration. Cancer Treat. Rep. (1982) 66:1719–1722.
   PubMedGoogle Scholar
• WEISS RB: Hypersensitivity reactions to cancer chemotherapy. Semin. Oncol. (1982) 9:5–13.
   PubMed Web of Science ®Google Scholar
• ZANOTTI KM, MARKMAN M: Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf (2001) 24:767–779.
   PubMed Web of Science ®Google Scholar
• SAUNDERS MP, DENTON CP, O'BRIEN ME, BLAKE P, GORE M, WILTSHAW E: Hypersensitivity reactions to cisplatin and carboplatin - a report on six cases. Ann. Oncol. (1992) 3:574–576.
   PubMed Web of Science ®Google Scholar
• MARKMAN M, KENNEDY A, WEBSTER K et al.: Clinical features of hypersensitivity reactions to carboplatin. J. Clin. Oncol. (1999)17:1141–1145.
   PubMed Web of Science ®Google Scholar
• •Description of the course of carboplatin-associated hypersensitivity reactions.
   Google Scholar
• CHANG SM, FRYBERGER S, CROUSE V, TILFORD D, PRADOS MD: Carboplatin hypersensitivity in children. A report of five patients with brain tumors. Cancer (1995) 75:1171–1175.
   Google Scholar
• MORGAN JS, ADAMS M, MASON MD: Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur. J. Cancer (1994) 30A:1205–1206.
   PubMed Web of Science ®Google Scholar
• POLYZOS A, TSAVARIS N, KOSMAS C et al.: Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Onco/ogy (2001) 61:129–133.
   Google Scholar
• FREEDMAN SO, KRUPEY J: Respiratory allergy caused by platinum salts. J Allergy (1968) 42:233–237.
   Google Scholar
• ORBAEK P: Allergy to the complex salts ofplatinum. A review of the literature and three case reports. Scand. J Work Environ. Health (1982) 8:141–145.
   PubMed Web of Science ®Google Scholar
• CROMWELL O, PEPYS J, PARISH WE, HUGHES EG: Specific IgE antibodies to platinum salts in sensitized workers. Clin. Allergy (1979) 9:109–117.
   PubMedGoogle Scholar
• MARKMAN M, BOOKMAN MA: Second-line treatment of ovarian cancer. Oncologist (2000) 5:26–35.
   PubMedGoogle Scholar
• DIZON DS, SABBATINI PJ, AGHAJANIAN C, HENSLEY ML, SPRIGGS DR: Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol. Oncol. (2002) 84:378–382.
   PubMed Web of Science ®Google Scholar
• ROBINSON JB, SINGH D, BODURKA-BEVERS DC, WHARTON JT, GERSHENSON DM, WOLF JK: Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol. Oncol. (2001) 82:550–558.
   PubMed Web of Science ®Google Scholar
• ROSE PG, FUSCO N, FLUELLEN L, RODRIGUEZ M: Carboplatin hypersensitivity reactions in patients with ovarian and peritoneal carcinoma. Int. J Gynecol. Cancer (1998) 9:365–368.
   Google Scholar
• GOLDBERG A, CONFINO-COHEN R, FISHMAN A, BEYTH Y, ALTARAS M: A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin. Immunol. (1996) 98:841–843.
   PubMed Web of Science ®Google Scholar
• WIESENFELD M, REINDERS E, CORDER M, Y00 T-J, DIETZ B, LOVETT J: Successful re-treatment with cis-dichlorodianimineplatinum(II) after apparent allergic reactions. Cancer Treat. Rep. (1979) 63:219–221.
   PubMedGoogle Scholar
• BROOME CB, SCHIFF RI, FRIEDMAN HS: Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med. Pediatr. OncoL (1996) 26:105–110.
   PubMedGoogle Scholar
• JONES R, RYAN M, FRIEDLANDER M: Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. GynecoL OncoL (2003) 89:112–115.
   PubMed Web of Science ®Google Scholar
• ZWEIZIG S, ROMAN LD, MUDERSPACH LI: Death from anaphylaxis to cisplatin: a case report. GynecoL OncoL (1994) 53:121–122.
   PubMed Web of Science ®Google Scholar
• ZANOTTI KM, RYBICKI LA, KENNEDY AW et aL: Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. j Gun. OncoL (2001) 19:3126–3129.
   Web of Science ®Google Scholar
• TOURNIGAND C, MAINDRAULT-GOEBEL F, LOUVET C, DE GRAMONT A, KRULIK M: Severe anaphylactic reactions to oxaliplatin. Eur. J. Cancer (1998) 34:1297–1298.
   PubMed Web of Science ®Google Scholar
• THOMAS RR, QUINN MG, SCHULER B, GREM JL: Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer (2003) 97:2301–2307.
   PubMed Web of Science ®Google Scholar
• EINHORN N, NILSSON B, HOLMB ERG K, LAMBERT B, EINHORN S: Risk of second tumors in a cohort of patients with ovarian carcinoma. Int. J. GynecoL Cancer (1996) 6:313–317.
   Web of Science ®Google Scholar
• CHAMBERS SK, CHOPYK RL, CHAMBERS JT, SCHWARTZ PE, DUFFY TP: Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer (1989) 64:2459–2461.
   PubMed Web of Science ®Google Scholar
• REED E, EVANS MK: Acute leukemia following cisplatin-based chemotherapy in a patient with ovarian cancer. J. Natl. Cancer Inst. (1990) 82:431–432.
   PubMed Web of Science ®Google Scholar
• PEDERSEN-BJERGAARD J, DAUGAARD G, HANSEN SW, PHILIP P, OLESEN LARSEN S, RORTH M: Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet (1991) 338:359–363.
   PubMed Web of Science ®Google Scholar
• TRAVIS LB, HOLOWATY EJ, BERGFELDT K et al.: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N EngL J Med. (1999) 340:351–357.
   PubMed Web of Science ®Google Scholar
• •Documents the risk of acute leukaemia following platinum-based chemotherapy for germ cell tumours.
   Google Scholar
• KALDOR JM, DAY NE, PETTERSSON F et al.: Leukemia following chemotherapy for ovarian cancer. N EngL J Med. (1990) 322:1–6.
   PubMed Web of Science ®Google Scholar
• COLON-OTERO G, MALKASIAN GD, EDMONSON JH: Secondary myelodysplasia and acute leukemia following carboplatin-containing combination chemotherapy for ovarian cancer. J NatL Cancer Inst. (1993) 85:1858–1860.
   PubMed Web of Science ®Google Scholar
• REIMER RR, HOOVER R, FRAUMENI JF Jr, YOUNG RC: Acute leukemia after alkylating-agent therapy of ovarian cancer. N EngL J Med. (1977) 297:177–181.
   PubMed Web of Science ®Google Scholar
• GREENE MH, BOICE JD Jr, GREER BE, BLESSING JA, DEMBO AJ: Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. A study of five randomized clinical trials. N EngL J Med. (1982) 307:1416–1421.
   PubMed Web of Science ®Google Scholar
• GERL A, MUHLBAYER D, HANSMANN G, MRAZ W HIDDEMANN W: The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer (2001) 91:1297–1303.
   PubMedGoogle Scholar
• WALLACE WH, SHALET SM, CROWNE EC, MORRIS-JONES PH, GATTAIVIANENI HR, PRICE DA: Gonadal dysfunction due to cis-platinum. Med. Pediatr. OncoL (1989) 17:409–413.
   PubMedGoogle Scholar
• TANGIR J, ZELTERMAN D, MA W, SCHWARTZ PE: Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet. GynecoL (2003) 101:251–257.
   PubMed Web of Science ®Google Scholar
• BREWER M, GERSHENSON DM, HERZOG CE, MITCHELL MF, SILVA EG, WHARTON JT: Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. j Clin. OncoL (1999) 17:2670–2675.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that fertility can be maintained following platinum-based chemotherapy for ovarian cancer.
   Google Scholar
• MITCHELL PL, AL-NASIRI N, NHERN R et al.: Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases. Cancer (1999) 85:2232–2244.
   PubMed Web of Science ®Google Scholar
• SEIDEN MV, SPITZER TR, MCAFEE S, FULLER AF: Successful pregnancy after high-dose cyclophosphamide, carboplatinum, and taxol with peripheral blood stem cell transplant in a young woman with ovarian carcinoma. GynecoL OncoL (2001) 83:412–414.
   PubMed Web of Science ®Google Scholar
• ZANOTTI KM, BELINSON JL, KENNEDY AW: Treatment of gynecologic cancers in pregnancy. Semin. OncoL (2000) 27:686–698.
   PubMed Web of Science ®Google Scholar
• WILLIAMS SF, SCHILSKY RL: Antineoplastic drugs administered during pregnancy. Semin. OncoL (2000) 27:618–622.
   PubMed Web of Science ®Google Scholar
• ODUNCU FS, KIMMIG R, HEPP H, EMMERICH B: Cancer in pregnancy: maternal-fetal conflict. J Cancer Res. Clin. OncoL (2003) 129:133–146.
   PubMed Web of Science ®Google Scholar
• CAVALLI F, TSCHOPP L, SONNTAG RW, ZIMMERMANN A: A case of liver toxicity following cis-dichlorodiarnmineplatinum(II) treatment. Cancer Treat. Rep. (1978) 62:2125–2126.
   PubMedGoogle Scholar
• TASSINARI D, SARTORI S, DRUDI G et al.: Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature. Ann. OncoL (1997) 8:1263–1267.
   PubMed Web of Science ®Google Scholar
• AL-LAMKI Z, PEARSON P, JAFFE N: Localized cisplatin hyperpigrnentation induced by pressure. A case report. Cancer (1996) 77:1578–1581.
   Google Scholar
• MARNOCHA RS, HUTSON PR: Intradermal carboplatin and ifosfamide extravasation in the mouse. Cancer (1992) 70:850–853.
   PubMed Web of Science ®Google Scholar
• PRETORIUS RG, HACKER NF, BEREK JS et al.: Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat. Rep. (1983) 67:1085–1092.
   PubMedGoogle Scholar
• CASPER ES, KELSEN DP, ALCOCK NW LEWIS JL Jr: Ip cisplatin in patients with malignant ascites: pharrnacokinetic evaluation and comparison with the i.v. route. Cancer Treat. Rep. (1983) 67:235–238.
   PubMedGoogle Scholar
• ALBERTS DS, LIU PY, HANNIGAN EV et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for Stage III ovarian cancer. N EngL J Med. (1996) 335:1950–1955.
   PubMed Web of Science ®Google Scholar
• •Documents the clinical utility and safety of cisplatin-based intraperitoneal therapy of advanced ovarian cancer.
   Google Scholar
• SPEYER JL, BELLER U, COLOMBO N et al.: Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J. Clin. Oncol (1990) 8:1335–1341.
   PubMed Web of Science ®Google Scholar
• PFEIFFER P, BENNEDBAEK O, BERTELSEN K: Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol (1990) 36:306–311.
   PubMed Web of Science ®Google Scholar